ArticleIranian journal of pathology2026
Primary Signet Ring Cell Carcinoma Bilateral Breast: An Exceptional Occurrence.
Article in Iranian journal of pathology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Signet ring cell carcinoma (SRCC) of the breast is an exceptionally rare subtype accounting for only 0.04% to 2.7% of all breast cancers. Pure SRCC is characterized by the presence of >90% signet ring cells and exhibits an aggressive clinical profile often associated with higher histologic grade, lympho-vascular invasion, hormone receptor positivity, and low HER2 expression. Differentiating primary mammary SRCC from metastases from gastrointestinal primary, especially in elderly patients with bilateral presentations is of prime importance. Immunohistochemistry plays a crucial role in this regard with primary breast SRCCs displaying ER, GATA3 and CK7 positivity and CK20 and CDX2 negativity. We report a case of bilateral signet ring cell carcinoma breast in an 82 year-old female. This case highlights the significance of recognising SRCC breast as a distinct pathological entity and thorough evaluation in case of bilateral presentation as it is exceptionally uncommon and poses diagnostic and therapeutic challenges.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.